PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsNadolol
Nadolol
Corgard, Corzide (nadolol) is a small molecule pharmaceutical. Nadolol was first approved as Corgard on 1982-01-01. It is used to treat angina pectoris, heart failure, hypertension, and myocardial infarction in the USA. The pharmaceutical is active against beta-2 adrenergic receptor and beta-1 adrenergic receptor. In addition, it is known to target beta-3 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Corgard (generic drugs available since 1993-10-31)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bendroflumethiazide
+
Nadolol
Tradename
Company
Number
Date
Products
CORZIDEKing PharmaceuticalsN-018647 DISCN1983-05-25
2 products, RLD
Hide discontinued
Nadolol
Tradename
Company
Number
Date
Products
CORGARDUS WorldMedsN-018063 RX1982-01-01
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nadolol and bendroflumethiazideANDA2016-04-15
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C07: Beta-adrenergic blocking agents
C07A: Beta blocking agents
C07AA: Beta blocking agents, non-selective
C07AA12: Nadolol
C07B: Beta blocking agents and thiazides
C07BA: Beta blocking agents, non-selective, and thiazides
C07BA12: Nadolol and thiazides
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Portal hypertensionD006975EFO_0000666K76.6134
Heart diseasesD006331EFO_0003777I51.944
Liver cirrhosisD008103EFO_0001422K74.044
Heart failureD006333HP_0001635I5033
Gastrointestinal hemorrhageD006471HP_0002239K92.2112
Diastolic heart failureD054144EFO_1000899I50.3022
Migraine disordersD008881EFO_0003821G43112
FibrosisD00535511
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Esophageal and gastric varicesD004932EFO_0009545I8511
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Smoking cessationD016540EFO_000431911
AsthmaD001249EFO_0000270J45111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10123
Healthy volunteers/patients22
Chest painD002637HP_0100749R07.911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.111
HypersensitivityD006967HP_0012393T78.4011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNadolol
INNnadolol
Description
Nadolol, sold under the brand name Corgard among others, is a medication used to treat high blood pressure, heart pain, atrial fibrillation, and some inherited arrhythmic syndromes. It has also been used to prevent migraine headaches and complications of cirrhosis. It is taken orally.
Classification
Small molecule
Drug classanalgesics (mixed opiate receptor agonists/antagonists); beta-blockers (propranolol type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
Identifiers
PDB
CAS-ID42200-33-9
RxCUI
ChEMBL IDCHEMBL649
ChEBI ID
PubChem CID39147
DrugBankDB01203
UNII IDFEN504330V (ChemIDplus, GSRS)
Target
Agency Approved
ADRB2
ADRB2
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
ADRB3
ADRB3
Organism
Homo sapiens
Gene name
ADRB3
Gene synonyms
ADRB3R, B3AR
NCBI Gene ID
Protein name
beta-3 adrenergic receptor
Protein synonyms
adrenergic, beta-3-, receptor, Beta-3 adrenoceptor, Beta-3 adrenoreceptor
Uniprot ID
Mouse ortholog
Adrb3 (11556)
beta-3 adrenergic receptor (Q9QZ98)
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Nadolol
+
Bendroflumethiazide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Nadolol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,713 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,535 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use